(Boursier.com) — The Equasens Group now owns:
76.11% of CAREMEDS (the acquisition of the balance of 23.89% is planned under conditions in Q4 2022)
100% from MULTIMEDS
100% of I-MEDS (CAREMEDS 60% and EQUASENS 40%)
The Equasens Group announces today that it has completed its acquisition of a majority stake in three of its subsidiaries.
Therapeutic compliance is a key issue at European level in the care of elderly patients or those suffering from chronic diseases.
This is why, in 2017, the Group strengthened its presence on the PDA (Preparation of Doses to Administer) market by acquiring a 51% stake in the capital of MULTIMEDS, an Irish company. This equity investment was accompanied by an equity investment of 51.82% in the capital of CAREMEDS, an English company.
These companies specialize in innovative technological development dedicated to therapeutic compliance. They ensure the overall control of the unit drug dispensing chain, from its production to the bedside of the patient:
-MULTIMEDS markets a manual PDA (Preparation of Doses to be Administered) solution with a complete and innovative pill box protected by patents;
-CAREMEDS is developing a secure Cloud platform for traceability of the drug circuit by pill box. Its eMAR system allows pharmacists in pharmacies as well as nurses or caregivers during dispensing in EHPADs to secure and ensure batch traceability of drugs prepared in pillboxes. The company has also developed a mobile application dedicated to retirement homes (CARE HOME).
If they are complementary, these solutions can also be marketed independently according to the needs of healthcare professionals and can be adapted according to the specificities of each country. These offers are now distributed in the United Kingdom, France, Spain, Italy, Portugal and Germany.
©2022 Boursier.com